Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Stock Information for Barinthus Biotherapeutics plc American Depositary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Barinthus Biotherapeutics plc American Depositary Shares

Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.